NCT03862885Approved For Marketing不适用
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
研究概览
简要总结
This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥ 16 years of age.
- •Diagnosis of unresectable or metastatic GIST
- •The patient is not eligible for an ongoing study of avapritinib or cannot access an ongoing study of avapritinib.
- •Patient has received 3 or more TKI therapies including imatinib, or the patient has GIST that carries a mutation in exon 18 of the PDGFRA gene (such as D842V).
- •The patient has adequate vital organ function, including heart, lungs, liver, kidneys, bone marrow and endocrine, and is expected to tolerate therapy with a TKI.
- •Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent.
排除标准
- •Patients who have poor organ function as defined by one or more of the following laboratory parameters;
- •Total bilirubin > 2 × ULN; or > 3 × ULN in the presence of Gilbert's Disease;
- •Platelet count < 75 × 10^9/L.
- •Patient requires therapy with a concomitant medication that is a strong inhibitor or strong inducer of cytochrome P450 (CYP) 3A4
- •Patient has had a major surgical procedure (minor surgical procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures) within 14 days of the first dose of avapritinib.
- •Patient has a history of a cerebrovascular accident or transient ischemic attacks within 1 year prior to the first dose of program drug.
- •Patient has a known risk of intracranial bleeding, such as a brain aneurysm or history of subdural or subarachnoid bleeding.
- •Women who are unwilling, if not postmenopausal or surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of randomization and for at least 30 days after the last dose of avapritinib. Men who are unwilling, if not surgically sterile, to abstain from sexual intercourse or employ highly effective contraception from the time of first dose and for at least 90 days after the last dose of avapritinib.
- •Women who are pregnant, as documented by a serum beta human chorionic gonadotropin (β-hCG) pregnancy test consistent with pregnancy, obtained within 7 days before the randomization. Females with β-hCG values that are within the range for pregnancy but are not pregnant (false-positives) may be enrolled with written consent of the Sponsor, after pregnancy has been ruled out. Females of non- childbearing potential (postmenopausal for more than 1 year; bilateral tubal ligation; bilateral oophorectomy; hysterectomy) do not require a serum β-hCG test.
- •Women who are breast feeding.
研究者
相似试验
No Longer Available
不适用
Expanded Access Program for AvapritinibSolid TumorsNCT04714086Blueprint Medicines Corporation
Available
不适用
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
Approved For Marketing
不适用
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT01931306Boehringer Ingelheim
No Longer Available
不适用
Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsSickle Cell DiseaseNCT03943615Pfizer
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.